{"favorite_id": 10086, "calc_type": "calculator", "dosing": false, "full_title_en": "BARD Score for NAFLD Fibrosis", "short_title_en": "BARD Score", "medium_description_en": "Predicts risk of advanced fibrosis in NAFLD patients.", "short_description_en": "Advanced fibrosis risk.", "before_use": "", "instructions_en": "", "purpose_en": ["Diagnosis"], "disease_en": ["Obesity", "Diabetes Mellitus", "Cirrhosis"], "specialty_en": ["Internal Medicine", "Hospitalist Medicine", "Family Practice", "Primary Care", "Hepatology", "Critical Care"], "chief_complaint_en": ["Abdominal Pain", "Fatigue"], "system_en": ["Endocrine and Metabolic"], "search_abbreviation_en": ["BARD", "fibrosis", "NAFLD", "Bard NAFLD", "Bard score"], "slug": "bard-score-nafld-fibrosis", "seo": {"meta_description_en": "The BARD Score for NAFLD Fibrosis predicts the risk of advanced fibrosis for NAFLD patients. ", "keywords_en": "BARD score, NAFLD, fibrosis, advanced fibrosis, bard"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-32db30a3-7fff-a8c5-a644-3db9f9054ea7\">Patients with suspected NAFLD.</span></p>", "pearls_pitfalls_en": "<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Strong negative predictive value for ruling out fibrosis (<a href=\"https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-10-67\" target=\"_blank\">Raszeja-Wyszomirska 2010</a>).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Original study involved mostly Caucasian patients and therefore score may be less applicable in other populations.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Doesn&rsquo;t predict fibrosis but rules out (high sensitivity).</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Helps differentiate adult patients with NAFLD from NASH who have not yet developed clinical stigmata of cirrhosis.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-fd44e89f-7fff-1f24-bdc6-c8e41532010d\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Predicts advanced fibrosis in NAFLD patients with a NPV of 97% (rules out fibrosis), thus potentially avoiding need for liver biopsy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Comparable to NAFLD Fibrosis Score in terms of sensitivity and specificity.</p>\n</li>\n</ul>"}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-ed435e45-7fff-645a-822e-96428aaf47cd\">Patients identified at high risk of fibrosis related to NAFLD can get focused interventions to prevent future complications through life style modifications.</span></p>", "management_en": "<p dir=\"ltr\">Lifestyle modifications include:</p>\n<p><span id=\"docs-internal-guid-8e942858-7fff-0259-795c-23e25836e94d\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tight glycemic control</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Blood pressure control</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Balanced diet</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regular aerobic exercise</p>\n</li>\n</ul>", "critical_actions_en": "<p><span id=\"docs-internal-guid-3210f454-7fff-2d23-5f11-6d814ccb5f6c\">Patients with advanced fibrosis can be monitored closely on the basis of BARD score for their disease progression and can be referred to liver transplant centers. </span></p>"}, "about": {"formula_en": "<p dir=\"ltr\">Addition of the selected points:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Variable</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Points</strong></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><calculator id=\"29\">BMI</calculator> &ge;28</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><abbr title=\"Aspartate aminotransferase\">AST</abbr>/<abbr title=\"Alanine aminotransferase\">ALT</abbr> ratio &ge;0.8</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\">Diabetes</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>BARD Score</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Risk of advanced fibrosis </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">0-1</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">2-4</p>\n</td>\n<td>\n<p dir=\"ltr\">High*</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p>*Scores 2-4 were associated with odds ratio (OR) 17 (95% CI 9.2-31.9) and 96% NPV (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/18390575\" target=\"_blank\">Harrison 2008</a>).</p>", "evidence_based_medicine_en": "<p><span id=\"docs-internal-guid-b88d8a08-7fff-9209-1a65-b9a3b4f11027\">The Bard Score was derived by <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/18390575\" target=\"_blank\">Harrison et al (2008)</a> in a retrospective study of 827 patients. All the patients had biopsy-proven NAFLD. A score of 2&ndash;4 was associated with an OR for advanced fibrosis of 17 (CI 9.2-31.9) and a negative predictive value of 96%. Limitations of the study include retrospective design, lack of population diversity, low sensitivity.</span></p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/18390575 ", "text": "Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441-7. "}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-10-67 ", "text": "Raszeja-wyszomirska J, Szymanik B, \u0141awniczak M, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010;10:67."}, {"href": "https://www.journal-of-hepatology.eu/article/S0168-8278(10)00718-X/abstract ", "text": "Ruffillo G, Fassio E, Alvarez E, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54(1):160-3."}, {"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560810/ ", "text": "Cicho\u017c-lach H, Celi\u0144ski K, Prozorow-kr\u00f3l B, Swatek J, S\u0142omka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012;18(12):CR735-40."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "", "firstName": "Ahmad", "img": "", "lastName": "Khan", "name": "Ahmad Khan, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Stephen A. Harrison", "creator_info": {"about_en": "Stephen A. Harrison, MD, is the medical director of Pinnacle Clinical Research. He is also a visiting professor of hepatology at the Radcliffe College of Medicine, University of Oxford. Dr. Harrison\u2019s research focuses primarily on hepatitis C and non-alcoholic fatty liver disease.", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-stephen-a-harrison.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Harrison+Stephen%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "<calculator id = \"29\">BMI</calculator> \u226528", "name": "bmi", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "textbox", "label_en": "<abbr title='Aspartate aminotransferase'>AST</abbr>", "name": "ast", "unit": "AST", "conditionality": "", "optional": false, "unit_info": {"name": "Aspartate Aminotransferase", "conversion": 1, "error_min": 1, "error_max": 10000, "warn_min": 4, "warn_max": 4000, "normal_max_si": 41, "normal_min_si": 15, "normal_min_us": 15, "units_si": "U/L", "units_us": "U/L", "normal_max_us": 41}}, {"type": "textbox", "label_en": "<abbr title='Alanine aminotransferase'>ALT</abbr>", "name": "alt", "unit": "ALT", "conditionality": "", "optional": false, "unit_info": {"name": "Alanine Aminotransferase", "conversion": 1, "error_min": 1, "error_max": 1000, "warn_min": 4, "warn_max": 400, "normal_max_si": 35, "normal_min_si": 1, "normal_min_us": 1, "units_si": "U/L", "units_us": "U/L", "normal_max_us": 35}}, {"type": "toggle", "label_en": "Diabetes", "name": "diabetes", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}], "md5": "f4874e437e09b9129375c9c9ff6c1979", "cmeVersion": "10086.1", "related_calcs": [{"calcId": 10068, "short_title_en": "NAFLD Activity Score", "slug": "nafld-non-alcoholic-fatty-liver-disease-activity-score"}, {"calcId": 3081, "short_title_en": "NAFLD Fibrosis Score", "slug": "nafld-non-alcoholic-fatty-liver-disease-fibrosis-score"}, {"calcId": 29, "short_title_en": "BMI & BSA", "slug": "body-mass-index-bmi-and-body-surface-area-bsa"}]}